PRECISELY Targeted Therapies for patients with cancer
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
We are passionate about using our expertise to address the needs of patients with cancer.
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsRead More >
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology DayRead More >
Nuvalent Announces Pricing of Public Offering of Common StockRead More >
Nuvalent Announces Public Offering of Common StockRead More >